替莫唑胺联合方案与拓扑替康顺铂方案治疗肺癌脑转移的对比研究  

Comparision about Temozolomide Based Chemotherapy and Topotecan/Cisplatin Regimen in the Treatment of Brain Metastatms from Non-Small-Cell Lung Cancer

作　　者：郭茜雪[1] 

机构地区：[1]辽宁省肿瘤医院内三科,沈阳市110042

出　　处：《中华全科医学》2012年第12期1834-1835,1853,共3页Chinese Journal of General Practice

基　　金：辽宁省自然科学基金(201003451)

摘　　要：目的比较替莫唑胺联合方案与拓扑替康顺铂方案对非小细胞肺癌脑转移的治疗效果。方法选择136例合并脑转移的非小细胞肺癌(non-small lung cancer,NSCLC)患者接受治疗,其中替莫唑胺联合方案组66例,拓扑替康顺铂方案组70例。结果替莫唑胺组完全缓解(CR)4例,部分缓解(PR)28例,总有效率48.5%,中位生存期10.1个月;拓扑替康组CR 6例,PR 26例,总有效率45.7%,中位生存期9.2个月。两组有效率及生存期差异均无统计学意义(P>0.05)。不良反应主要为骨髓抑制,两组比较差异无统计学意义(P>0.05)。结论替莫唑胺联合方案治疗肺癌脑转移疗效肯定,其近期疗效和长期生存率与拓扑替康顺铂方案组相似,耐受性较好。Objective To compare the clinical efficacy of Temozolomide based chemotherapy and Topotecan/Cisplatin regi- men in the treatment of brain metastasis from non-small-cell lung cancer. Methods A total of 136 NSCLC patients with brain metastasis from non-small-cell lung cancer were included ;66 patients received Temozolomide based chemotherapy and 70 patients received Topotecan/Cisplatin regimen. Results The overall response rate was 48.5% in group of Temozolomide based chemo- therapy, with 4 complete response（CR） and 28 partial response （PR）, and 45.7% in the TopotecalCCisplatin group with 6 CR and 26 PR（ P 〉 0.05 ）. The median duration of survival was 10.1 months in group of Temozolomide based chemotherapy versus 9.2 months in Topotecan/Cisplatin group （ P 〉 0.05 ）. The main toxicity was myelosuppression. Conclusion Temozolomide based chemotherapy was a highly active regimen for treatment of brain metastasis from non-small-cell lung cancer;there was no difference in the effectiveness and toxicity versus Topotecan/Cisplatin Regimen.

关 键 词：NSCLC 脑转移 替莫唑胺 拓扑替康 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]